Recently, Bosch Company announced that its newly developed COVID-19 automatic rapid detection scheme can help medical institutions to realize rapid diagnosis, effectively improve the speed of identifying and isolating infected people, and thus help to control the epidemic trend in COVID-19.
It is reported that Bosch's latest rapid detection scheme was developed in only six weeks. It takes only 2.5 hours to judge whether the patient is positive for COVID-19 from sample collection to result presentation. This brand-new rapid detection scheme is one of the earliest automatic molecular diagnosis detection schemes in the world, which is suitable for all medical institutions.
Although many testing schemes on the market have reached the fastest time of 15 minutes, Volkmar Dunnell, chairman of the board of directors of Bosch Group, said: "Another advantage of rapid testing is that it allows testing at the point of care, thus eliminating the need for sample transportation and winning valuable time for treatment. This is a huge advantage of Bosch solutions. "
According to reports, in all laboratory tests aimed at COVID-19, the accuracy rate of Bosch's rapid testing scheme is over 95%, and the testing scheme meets the quality standards of the World Health Organization (WHO). Moreover, the operation of this analytical equipment is very simple, and even medical personnel without special operation training can get reliable test results.
The specific operation flow of this detection scheme is that after sampling from the patient's nasal cavity or throat with a cotton swab, the kit containing all the reagents needed for detection is inserted into the in vivo analysis equipment, so that a Bosch in vivo analysis equipment can carry out as many as 10 tests within 24 hours.
In addition to COVID-19 samples, this rapid detection scheme can also detect nine other respiratory diseases, such as influenza A and influenza B. Bosch said that this newly developed test scheme will be launched in Germany from April, and then in Europe and other parts of the world.
At present, COVID-19 has spread all over the world and is in urgent need of a large number of medical supplies. At present, many car companies including GM, Ford, Lamborghini, Tesla, Volkswagen, McLaren, Ferrari and Fiat Chrysler have begun to invest in the transformation of medical materials, and even some luxury brands have joined the production camp.
Even when the United States failed to reach an agreement with GM, it directly and formally used the administrative power given by the National Defense Production Law to require American automobile companies such as GM, Ford and Tesla to switch to ventilators. It is reported that GM and Ford, two automobile giants, will produce more than 50,000 ventilators in the next year.
In addition to the United States, the German government also requires domestic automobile manufacturers to consider producing medical equipment, such as masks or ventilators, to combat the rapidly spreading novel coronavirus epidemic. This requirement is part of the larger-scale measures taken by the German government to develop engineering and production resources and solve the serious supply bottleneck of key medical equipment. For example, Volkswagen has started to build the production capacity of protective masks in China, and will provide thermometers, masks, disinfectants and diagnostic equipment to the German authorities.
The spread of COVID-19 in the world has had a great impact on the whole world automobile industry. Even if many car companies can produce new cars as scheduled, the final products may not be sold as scheduled, so it is not a good choice to produce urgently needed medical materials instead. The greater the global ability to fight the epidemic, the greater the responsibility!
This article comes from car home, the author of the car manufacturer, and does not represent car home's position.